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Abstract
Lung cancer is a leading cause of cancer death worldwide. Several alterations in RNA metabolism have been found in lung
cancer cells; this suggests that RNA metabolism-related molecules are involved in the development of this pathology. In this
study, we searched for RNA metabolism-related genes that exhibit different expression levels between normal and tumor
lung tissues. We identified eight genes differentially expressed in lung adenocarcinoma microarray datasets. Of these, seven
were up-regulated whereas one was down-regulated. Interestingly, most of these genes had not previously been associated
with lung cancer. These genes play diverse roles in mRNA metabolism: three are associated with the spliceosome (ASCL3L1,
SNRPB and SNRPE), whereas others participate in RNA-related processes such as translation (MARS and MRPL3), mRNA
stability (PCBPC1), mRNA transport (RAE), or mRNA editing (ADAR2, also known as ADARB1). Moreover, we found a high
incidence of loss of heterozygosity at chromosome 21q22.3, where the ADAR2 locus is located, in NSCLC cell lines and
primary tissues, suggesting that the downregulation of ADAR2 in lung cancer is associated with specific genetic losses.
Finally, in a series of adenocarcinoma patients, the expression of five of the deregulated genes (ADAR2, MARS, RAE, SNRPB
and SNRPE) correlated with prognosis. Taken together, these results support the hypothesis that changes in RNA
metabolism are involved in the pathogenesis of lung cancer, and identify new potential targets for the treatment of this
disease.
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Introduction
Lung cancer is one of the most common human cancers and a
leading cause of cancer death worldwide [1,2]. It includes two
principal histological subtypes, small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC), and the latter accounts for
80–85% of all cases. Lung cancer is often detected at an advanced
stage, at which point the disease is nearly incurable. Further
characterization of the biological alterations associated with its
pathogenesis could potentially help identify new biomarkers for
early diagnosis and new targets for more effective therapies.
Alternative splicing is a biological process essential for protein
diversity. Through alternative splicing, multiple transcripts are
generated from a single mRNA precursor. Alterations in
alternative splicing have been demonstrated to be associated with
various diseases, including cancer. Several alternatively spliced
gene products have been linked to the development of neoplastic
disease [3]. Cancer-associated splice variants may potentially serve
as diagnostic and prognostic tools as well as therapeutic targets in
cancer [4]. In lung cancer, many splicing alterations have been
previously described in cancer-related processes such as cell
growth, cell cycle control, apoptosis, or angiogenesis [5–9]. For
example, high levels of the anti-apoptotic variant Bcl-xL have been
reported to contribute to tumor progression in both SCLC and
NSCLC [10,11]. Recently, splicing changes that affected tran-
scripts of VEGFA, MACF1, APP, and NUMB were demonstrated
in patients with lung adenocarcinoma [9]. Moreover, the
expression of a specific isoform of NUMB in tumor samples was
shown to promote cell proliferation [9]. In addition, modulation of
caspase 9 alternative splicing was demonstrated to affect the
sensitivity of NSCLC cells to some chemotherapeutic agents [12].
The mechanisms underlying aberrant alternative splicing in
lung cancer remain poorly understood. In some cases, mutations
in splicing regulatory elements within the nucleotide sequence of
the gene result in modifications in splice site selection, in turn
leading to alternatively spliced transcripts [13]. In other cases,
changes in proteins related to mRNA-metabolism are responsible
for the abnormal splice patterns. Some studies have reported
changes in the concentration, localization, composition or activity
of several RNA-binding proteins in lung cancer [14–19],
suggesting that this pathway is frequently altered and is important
for malignant transformation. The RNA binding protein SF2/
ASF is overexpressed in NSCLC tumors and promotes survival by
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enhancing survivin expression [18]. Studies in animal models
suggest that altering the balance between different RNA-binding
proteins contributes to lung carcinogenesis [20,21]. However,
characterization of the repertoire of RNA metabolism-related
molecules involved in lung cancer is currently incomplete, and
further studies are warranted.
In this study, we aimed to identify new RNA metabolism-
related genes with altered expression in primary lung tumors.
Using lung adenocarcinoma microarray datasets, we searched for
genes that exhibited significantly different expression levels
between normal and tumor lung tissues. We identified seven
mRNA metabolism-related proteins up-regulated in tumor tissues
and one down-regulated. Some of the over-expressed genes belong
to the family of spliceosomal proteins, implicating this cellular
machinery in the development of NSCLC. The downregulated
gene ADAR2 was located in an area with a high frequency of
deletions in NSCLC. In addition, the expression of five of these
genes was associated with the prognosis of patients with lung
adenocarcinoma, supporting the importance of RNA metabolism
in lung cancer biology.
Results
Gene Selection by Bioinformatics Analysis
Genes belonging to RNA metabolism-related categories were
selected from the Gene Ontology database (www.godatabase.org).
Three major RNA metabolism-related categories were chosen:
‘‘RNA binding’’, ‘‘RNA splicing’’, and ‘‘spliceosome complex’’.
The fold-change (FC) of gene expression levels between normal
and adenocarcinoma lung tissue was calculated using data from
three microarray experiments [22–24]. A set of genes with mRNA
expression levels significantly different between normal and cancer
tissues was obtained from each of the three microarray
experiments (Table S1). A representative example is shown in
Figure 1A, and the overlap between the different lists is shown in
Figure 1B. Additionally, we found that these genes were
differentially expressed in squamous cell carcinoma, small-cell
lung carcinoma, and carcinoid cases present in the datasets (data
not shown). To corroborate the validity of this selection, additional
in silico validation was performed with a fourth independent cohort
of lung adenocarcinoma patients [25], and the results confirmed
the findings of the initial experiment (Table S2).
Expression of Selected RNA Metabolism-related Genes in
Lung Cancer Cell Lines and Normal Lung Primary
Cultures
Expression levels of the selected genes were evaluated by
conventional PCR in SCLC and NSCLC cell lines and in primary
NHBE cells. For most genes, mRNA levels in lung cancer cell lines
were higher than in NHBE cells (Figure 2). Moreover, mRNA
levels were generally higher in SCLC cell lines compared to
NSCLC cell lines. This result is in concordance with previous
observations in which the expression levels of other RNA-binding
proteins were also determined to be higher in SCLC compared to
NSCLC [15]. In ADAR2, several lung cancer cell lines exhibited
lower mRNA levels compared to NHBE cells. We excluded
RNPS1 and SNRPC in subsequent analyses because expression
levels were homogeneous among all cell types.
To quantify differences in expression levels, real time PCR for
each of the eight selected genes was performed in the panel of lung
cancer cell lines, as well as in NHBE cells and normal primary
SAECs. This analysis confirmed our previous results: expression of
the up-regulated genes was higher in lung cancer cells compared
to NHBE cells or SAECs. In contrast, ADAR2 expression in lung
cancer cells was lower than in NHBE cells or SAECs (Figure 3).
Genetic Alterations at the ADAR2 Locus
We characterized the genetic alterations associated with
ADAR2 down-regulation in lung cancer. Thus, we evaluated the
presence of LOH at 21q22.3, the location of the ADAR2 locus.
We used a panel of eight heterozygous microsatellites. Microsat-
ellites were amplified by PCR and analyzed using capillary
electrophoresis. Microsatellite heterozygosity was initially evaluat-
ed in the panel of lung cancer cell lines and the results are shown
in Figure 4. In six cell lines (H23, HCC827, A549, H322, H1385,
and H1299), all microsatellites were homozygous. Although the
presence of loss of heterozygosity (LOH) is not definitively
conclusive due to the lack of matched normal genomic DNA,
this homozygosity is extremely unlikely and strongly suggests a loss
of genetic material. In other cell lines the results were variable, and
certain cases suggested localized areas of LOH (e.g., the most
centromeric region in H157 cells). Next, we compared the
homozygosity at 21q22.3 and ADAR2 mRNA expression levels
(previously obtained). All cell lines homozygous for the microsat-
ellites expressed low ADAR2 mRNA levels. In fact, two of the
three cell lines with the lowest ADAR2 mRNA expression levels
(A549 and H1385) belong to this group. In contrast, the five cell
lines with the highest ADAR2 expression levels (H82, H187,
H157, H226 and H460) were mostly heterozygous for the
microsatellites flanking the ADAR2 locus (D21S171 and
D21S1574).
We studied the presence of homozygosity at 21q22.3 in genomic
DNA from 48 patients with lung cancer. The evaluation of the
eight microsatellites in tumor tissues and matched normal tissues
allowed us to precisely determine the frequency of LOH at this
chromosomal region. Figure 5A illustrates the three alternative
electrophoretic patterns obtained: non-informative case, retention
of heterozygosity, and LOH. After microsatellite analysis, LOH
was identified in approximately 30–40% of cases (Figure 5B).
LOH at 21q22.3 was significantly higher in squamous cell
carcinomas than in adenocarcinomas (2566% vs. 4967%,
p = 0.003). No differences in the frequency of LOH were found
between stages (stage I: 3762% vs. stages II–III: 3467%,
p = 0.279). To evaluate the ADAR2 locus more specifically, a
SNP located within the ADAR2 gene (rs1051367) was analyzed.
Of the twenty informative cases (i.e., cases heterozygous for SNP
rs1051367 in normal tissue), fifteen (75%) were homozygous in the
corresponding matched tumor tissue. A comparison between the
results obtained from the microsatellite analysis and SNP
sequencing demonstrated concordance between the respective
techniques, although the number of patients with LOH at the
ADAR2 SNP was higher (30–40% vs. 75%).
Expression of RNA Metabolism-related Genes and Lung
Cancer Clinical Outcome
We investigated whether expression of the differentially
expressed RNA metabolism-related genes was associated with
clinical outcomes in patients with lung adenocarcinoma using a
publicly available microarray data [26]. Patients were divided
according to high and low mRNA expression levels using the
median as the cut off point (Figure 6). In the case of ASCC3L1,
MRPL3, and PABPC1, no association was found between mRNA
levels and patient clinical outcome (data not shown). High
expression of MARS, RAE1, SNRPB, and SNRPE was signifi-
cantly associated with reduced overall survival. High ADAR2
mRNA levels were significantly associated with a better outcome.
For a combined analysis of the five prognostic genes, patients were
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divided into three groups: patients with no deregulating events,
patients with one to three events, and patients with four or five
events. The combined score of the five genes was a strong
prognostic marker (Figure 6). Thus, patients with no deregulating
events exhibited very good survival. In contrast, patients with
deregulation in four or five of the genes exhibited the worst
survival. The Cox proportional hazards model was used to assess
the impact of the prognostic score on overall survival, in both
univariate and multivariate analysis (Table 1). The RNA-
metabolism score was an independent prognostic factor for overall
survival in patients with lung adenocarcinoma.
Discussion
We identified eight RNA-related genes differentially expressed
in lung cancer, a finding that supports the hypothesis that RNA
metabolism is important in the pathogenesis of lung cancer. Seven
of the identified genes were up-regulated, whereas only one was
down-regulated. Interestingly, most of these genes had not been
previously reported to be associated with lung cancer. Addition-
ally, the expression of the majority of these genes exhibited an
association with overall survival in lung adenocarcinoma patients,
suggesting a connection between RNA metabolism and lung
cancer pathogenesis.
Previous reports have demonstrated that RNA-metabolism
genes are deregulated and implicated in malignant transformation
of lung cells [14,16,18]. The findings in our study identify a new
set of differentially-expressed genes associated with RNA-metab-
olism. It is clear that the expression of many other RNA-related
genes is altered in lung cancer. The group of genes identified in
our study was strongly influenced by the stringent strategy of
selection. Statistical analyses were restrictive; thus, only the most
significant genes were chosen. Moreover, changes in splicing,
which have been reported for some RNA-related genes [17,27,28],
cannot be detected using this analytical approach.
Most of the RNA-related genes identified in our study were up-
regulated in tumor tissue. The reason for this is unclear; it may be
due to the increased metabolic rate associated with tumor cell
proliferation. However, the vast majority of RNA-related genes
exhibited no differences between tumor and normal lung tissues.
Moreover, one relevant gene identified in our study was
downregulated (ADAR2), and mRNA expression of five of the
selected genes was associated with clinical outcome in a series of
adenocarcinoma patients. In particular, high expression of up-
regulated genes (MARS, RAE1, SNRPB, and SNRPE) was
associated with worse prognosis, whereas high expression of the
downregulated gene (ADAR2) correlated with improved survival.
Interestingly, the group of patients with no deregulation in any of
these genes exhibited very good survival. On the other hand, a
high number of deregulating events was associated with poor
survival. These results suggest that the activity of the RNA-
metabolic machinery could potentially serve as a prognostic
marker for lung cancer.
Figure 1. Gene selection by bioinformatics analysis. A) RNA-related genes with expression levels significantly different (p,0.01) between lung
adenocarcinoma samples and normal lung samples (last 10 columns) in one of the microarray databases used in the study [23]. Red color denotes
higher expression levels, whereas green color indicates lower expression levels. B) Venn diagram corresponding to genes with significant expression
differences between normal and adenocarcinoma samples.
doi:10.1371/journal.pone.0042086.g001
Figure 2. PCR expression analysis of RNA metabolism-related genes. Expression levels were determined in lung cancer cell lines and normal
human bronchial epithelial (NHBE) cells. GAPDH was used as control gene. SCLC: small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell
carcinoma; LCC: large cell carcinoma; CT: carcinoid tumor; NC: negative control (water).
doi:10.1371/journal.pone.0042086.g002
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Proteins translated from three of the eight up-regulated genes
belong to the family of spliceosomal small nuclear ribonucleopro-
teins (snRNPs): ASCC3L1, SNRPB, and SNRPE. The spliceo-
some is a complex of snRNPs plus a multitude of associated
proteins. This complex recognizes splice sites and removes introns
from pre-mRNA molecules. Little is known regarding the role
played by the spliceosome in cancer. Recently, using whole-exome
sequencing analysis, some studies have identified a high frequency
of mutations in distinct components of the spliceosome in chronic
lymphocytic leukemia and myelodysplasia [29–33], implicating
this cellular machinery in the development of cancer [34]. Thus,
some spliceosomal inhibitors have been tested in cancer cells and
the spliceosome has been proposed as an anti-cancer target [35].
The identification of three spliceosomal proteins differentially
expressed in lung cancer suggests that a role is played by the
spliceosome in this malignancy. Unfortunately, there is little
published information concerning the role of these particular
proteins in cancer. ASCC3L1 (SNRNP200) encodes helicase Brr2,
an important component of the spliceosomal snRNP U5. To our
knowledge, this study is the first to demonstrate than ASCC3L1 is
associated with malignancy. Small nuclear ribonucleotide associ-
ated protein B (SNRPB) is part of snRNP U1. SNRPB has been
reported to be a metastasis suppressor in a mouse allograft model
of prostate cancer [36]. A rare polymorphism in the SNRPB gene
has been associated with reduced risk of breast cancer in BRCA1
mutation carriers [37]. The overexpression of small nuclear
ribonucleotide associated protein E (SNRPE) has been reportedly
associated with growth arrest at G2 phase in both malignant and
non-malignant cells [38]. However, in line with our results,
SNRPE is amplified and overexpressed in malignant gliomas and
oral squamous cell carcinomas [39,40]. SNRPE is also amplified
and up-regulated in hepatocellular carcinoma and may function as
an oncogene by enhancing cell proliferation [41].
The other proteins that were up-regulated in our study were
MARS, MRPL3, PABPC1 and RAE. Methionine-tRNA synthe-
tase (MARS or MetRS) acts as a catalyst in the binding of
methionine to its corresponding tRNA. Increased activity of this
enzyme has been reported in human colon cancer [42]. More
recently, an induction of MARS expression was shown in breast
cancer cell lines stimulated with insulin-like growth factor [43].
Frameshift mutations in MARS have been described in gastric and
colorectal carcinomas with microsatellite instability [44]. Mito-
chondrial ribosomal protein L3 (MRPL3) is a component of the
39S subunit of the mitochondrial ribosome. High expression of
this protein has been reported in hepatocarcinoma, colon
carcinoma, and lymphoma, suggesting an association of this
protein with high cell division rates [45]. Poly-A binding protein
cytoplasmic 1 (PABPC1) participates in poly-A shortening at the 39
end of eukaryotic mRNAs. Contradictory results regarding the
role of this protein in cancer have been reported. One study
concluded that low levels of PABPC1 correlated with more
invasive tumors and worse survival rates in patients with
esophageal cancer [46]. However, in other studies, PABPC1
over-expression was described in prostate tumors [47], hepatocel-
lular carcinoma [48], superficial bladder cancer [49], and lung
cancer [50]; in the latter report the authors suggested the
participation of the translation initiation complex in the tumor-
igenesis of lung cancer. PABPC1 also regulates telomerase activity,
leading to a growth advantage in keratinocytes expressing human
papillomavirus type 16 E6 [51]. RNA export 1 homolog (RAE1) is
a nuclear export protein involved in mRNA transport from the
nucleus to the cytoplasm. RAE1 also plays a critical role in the
maintenance of spindle bipolarity during cell division [52,53].
RAE1 mRNA and protein levels decrease upon inhibition of
neuroblastoma cell proliferation, and its overexpression prevents
retinoic acid-induced cell cycle arrest and differentiation [54];
however, a previous study demonstrated that RAE1/NUP98
Figure 3. Real time PCR expression analysis of RNA metabolism-related genes. Expression levels were determined in lung cancer cell lines
and non-malignant lung primary cultures (NHBE and SAEC). HPRT was used as control gene. Bars represent normalized expression ratios relative to
gene levels in NHBE cells. Ratios .1 indicate higher expression levels than in NHBE cells, whereas ratios ,1 denote lower expression levels.
doi:10.1371/journal.pone.0042086.g003
Figure 4. Analysis of microsatellites at 21q22.3 in lung cancer cell lines. Homozygosity (green) or heterozygosity (red) was determined in
each cell line. Microsatellites are ordered from the most centromeric to the most telomeric. ADAR2 locus is located within D21S171 and D21S1574.
doi:10.1371/journal.pone.0042086.g004
RNA Metabolism-Related Genes in Lung Cancer
PLoS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e42086
mutant mice are more susceptible to DMBA-induced lung tumors
compared to wild-type mice, indicating that combined RAE1/
NUP98 haplo-insufficiency potentially promotes tumorigenesis
[55].
The downregulated gene adenosine deaminase acting on RNA
2 (ADAR2 or ADARB1) is an RNA editase that catalyzes
adenosine to inosine deamination in double-stranded regions.
Dysregulation of adenosine to inosine editing in human cancers
potentially contributes to the altered transcriptional program
necessary to sustain carcinogenesis [56]. ADAR2 is ubiquitously
expressed in many tissues, particularly in the central nervous
system [57]. Early onset epilepsy and premature death were
reported in ADAR2 knock out mice [58]. In cancer, a previous
study reported overexpression of ADAR2 in in vitro transformed
human adult mesenchymal stem cells, transformed fibroblasts, and
some cell lines from other tissues [59]. Higher levels of ADAR2
mRNA were also observed in androgen-independent prostate
cancer cell lines relative to androgen-responsive cell lines [60].
However, most reports link cancer with reduced ADAR2
expression or activity. Thus, a decrease in enzymatic activity of
ADAR2 in patients with multiform glioblastoma (MGB) was
associated with higher Ca2+ permeability and activation of the Akt
pathway, contributing to tumor growth and aggressiveness
[61,62]. Paz et al. also found a decrease of ADAR2 mRNA levels
in brain tumors and demonstrated that its overexpression in an
MGB cell line resulted in decreased cell proliferation [63]. A
decrease in ADAR2 editing activity, which correlated with the
grade of malignancy, was also found in pediatric astrocytomas
[64]. When the editing status was reverted in three astrocytoma
cell lines, a significant decrease in cell malignant behavior was
found [64]. More recently, Galeano et al. observed a general
decrease in ADAR2-mediated editing events in bladder and
colorectal cancer [65]. In the case of lung cancer, a reduction of
ADAR2 expression was previously described in squamous cell lung
carcinoma [66].
Downregulation of ADAR2 in lung cancer is potentially
associated with genetic alterations at 21q22, where the ADAR2
gene is located. Previous studies have reported the loss of
genetic material at the long arm of chromosome 21 in patients
with several solid tumors [67–71], including lung cancer [72–
76]. Lee et al. analyzed nine microsatellite markers, placed
between 21q21.1 and 21q22.3 in NSCLC patients. LOH was
detected for at least one of them in over 55% of tumors, with
26%–48% LOH incidence rate in individual microsatellites
[74]. Sato et al. described LOH at 21q22.3 in 28% of samples
from adenocarcinoma and squamous cell carcinoma patients
[72]. We focused on the analysis of 21q22.3 alterations in the
region of ADAR2. We found 30–40% incidence of LOH
among patients with NSCLC, with almost half of the tumors
(23 out of 48) exhibiting LOH in at least one of the
microsatellites analyzed. In accordance with previous studies,
squamous cell carcinomas showed higher frequencies of LOH at
21q22 than adenocarcinomas. In addition, a very high
incidence of LOH (75%) was observed upon analysis of a
SNP located within the ADAR2 gene. These results can be
explained by the existence of alternating regions with and
without LOH, and indicate that the ADAR2 genetic locus is
one of the most frequently altered regions in lung carcinogen-
esis. Taken together, the frequent genetic losses at the ADAR2
locus and its reduced expression suggest that ADAR2 potentially
functions as a tumor suppressor in lung cancer. Functional data
also support this hypothesis, because overexpression of ADAR2
in cancer cell lines inhibits proliferation and migration [63,64].
Moreover, we have demonstrated that low ADAR2 mRNA
Figure 5. Analysis of LOH at 21q22.3 in lung cancer patients. Genomic DNA from primary lung cancers and their corresponding normal lung
tissues were used. A) Representative examples of the electrophoretic patterns obtained by microsatellite analysis: a non-informative case, with only
one amplification peak; heterozygosity retention, with two peaks in both normal and tumor samples; and LOH, with two peaks in the normal sample
but only one peak in the corresponding tumor sample. Arrows point to microsatellite alleles. B) LOH of the indicated microsatellites was analyzed in
48 NSCLC patients. Microsatellites are ordered from the most centromeric to the most telomeric. LOH at the ADAR2 locus was analyzed by direct
sequencing of the polymorphism rs1051367 (A/G). Green boxes represent LOH, red boxes indicate retention of heterozygosity, and yellow boxes are
non-informative loci.
doi:10.1371/journal.pone.0042086.g005
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Figure 6. Association between RNA metabolism-related genes and clinical outcome of patients with lung adenocarcinoma. Data
were obtained from a microarray study [26]. Figures show Kaplan-Meier curves and log rank statistics for overall survival in patients divided in high
and low mRNA expression (using the median as the cut-off point). Last figure corresponds to patients divided by the number of deregulating events
(see Material and Methods).
doi:10.1371/journal.pone.0042086.g006
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levels are significantly associated with overall survival in lung
adenocarcinoma patients. A prognostic score based on the
expression of ADAR2 and four additional RNA metabolism-
related genes (MARS, RAE1, SNRPB and SNRPE) can stratify
lung cancer patients into high and low risk groups for cancer
death. Additional research is warrant to examine whether this
information can be useful to identify those patients with
resectable NSCLC who are at high risk of recurrence and
would benefit from adjuvant therapy.
In conclusion, in this study we identified new RNA metabolism-
related genes differentially expressed in lung cancer and associated
with clinical outcome. These results support the role of RNA
metabolism in the pathogenesis of this disease. Further character-
ization of the mechanisms regulating this process may potentially
lead to the development of improved strategies for diagnosis,
prognosis, and treatment of lung cancer.
Materials and Methods
Ethics Statement
This study was approved by the ethics committees of the Clı´nica
Universidad de Navarra (Pamplona, Spain) and the Hospital
Marque´s de Valdecilla (Santander, Spain). Written informed
consent was obtained from each patient.
Microarray Experiments
Four publicly available microarray experiments were used to
identify RNA-metabolism related genes differentially expressed
between lung adenocarcinoma and normal lung tissue [22–25].
Some of these experiments included data from other histological
subtypes. A fifth microarray experiment was used to analyze the
relationship between gene expression levels and prognosis in
patients with lung adenocarcinoma [26]. Table S3 contains
information about the number of samples and the histological
subtypes present in each study.
Lung Cancer Cell Lines and Primary Cultures
Lung cancer cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Cells were grown in
RPMI supplemented with 2 mM glutamine, 10% fetal bovine
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (Invi-
trogen, Carlsbad, CA). Small airway epithelial cells (SAEC) were
purchased from Lonza (Walkersville, MD) and cultured in small
airway epithelial growth medium (SAGM, Lonza) supplemented
with SAGM SingleQuots (Lonza). Normal human bronchial
epithelial (NHBE) cells (Clonetics, San Diego, CA) were grown in
bronchial epithelial cell growth medium (BEGM, Clonetics)
complemented with the growth supplements of the BulletKit
(Clonetics). Cell cultures were maintained at 37uC and 5% CO2 in
a humidified incubator. Before RNA or DNA extraction, cells
were tested for Mycoplasma contamination, according to manufac-
turer’s instructions (MycoAlert Mycoplasma Detection Kit,
Cambrex, Rockland, ME).
Clinical Samples
Primary tumors and their corresponding normal lung tissues
were obtained from patients with NSCLC treated with curative
resectional surgery at the Clı´nica Universidad de Navarra
(Pamplona, Spain) or at the Hospital Marque´s de Valdecilla
(Santander, Spain). None of the patients received chemo- or
radiotherapy prior to surgery. Surgically removed samples were
immediately frozen in liquid nitrogen and stored at 280uC until
use. Only samples containing more than 70% tumor cells were
used. Histologies and stages of the tumors included in the study are
listed in Table S4. Tumors were classified according to WHO
2004 classification [77].
RNA Extraction
RNA extraction was performed using RNA Ultraspec (Biotecx
Laboratories, Houston, TX). For primary tissues, RNA extraction
was carried out after mechanical fragmentation of frozen samples,
using b-mercaptoethanol and RNeasy Micro (Qiagen, Hilden,
Germany), according to manufacturer’s instructions. All RNA
samples were diluted in water with DEPC and stored at 280uC
until use. RNA concentration was determined by spectrophotom-
etry (Nanodrop, Thermo Scientific, Wilmington, DE).
Reverse Transcription (RT)
Two micrograms of RNA were incubated with 1 mM dNTPs
and 50 ng/mL oligo-dTs at 65uC for 5 minutes. Afterwards, 4 mL
Table 1. Cox proportional-hazards models for association of
the RNA metabolism prognostic score and the clinical
outcome of patients with lung adenocarcinoma, in both
univariate and multivariate analysis.
Hazard ratio (95% CI) p
Univariate analysis
Age
#70
.70 1.36 (0.83–2.24) 0.220
Gender
Female
Male 1.22 (0.76–1.97) 0.413
Smoking status 0.387
Never smoker
Former 1.27 (0.58–2.81) 0.549
Current 1.90 (0.69–5.25) 0.214
Stage ,0.001
I
II 3.07 (1.74–5.44) ,0.001
III 5.74 (3.01–10.94) ,0.001
Differentiation grade
Well-differentiated
Moderately 1.26 (0.62–2.55) 0.520
Poorly 1.51 (0.71–3.19) 0.283
Prognostic score ,0.001
0
1–3 7.49 (1.02–54.85) 0.048
4–5 16.03 2.19–117.02) 0.006
Multivariate analysis
Stage ,0.001
I
II 2.82 (1.59–5.01) ,0.001
III 8.89 (4.47–17.35) ,0.001
Prognostic score ,0.001
0
1–3 8.49 (1.15–62.44) 0.036
4–5 22.70 (3.06–168.34) 0.002
doi:10.1371/journal.pone.0042086.t001
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of 56RT buffer, 1 mL of 0.1 M DTT, 40 U of RNase Out and
200 U of Super Script III reverse transcriptase (all from
Invitrogen) were added. Tubes were incubated 50 minutes at
50uC and 15 minutes at 70uC, and then placed into ice. Finally,
2 U of RNase H (Invitrogen) were added, and tubes were
incubated 20 minutes at 37uC. cDNA was stored at 220uC until
use.
Genomic DNA Extraction
Genomic DNA was purified with the QIAamp DNA Mini Kit
(Qiagen), following manufacturer’s instructions. Extraction of
genomic DNA from clinical samples was performed after
mechanical fragmentation using the protocol described above.
DNA concentration was determined by spectrophotometry
(Nanodrop).
Conventional PCR
Gene expression was assessed by conventional PCR. GAPDH
was used as control gene. Primer sequences are shown in Table
S5. The reaction mixture consisted of 1 mL of cDNA, 5 mL of 106
buffer (Bioline, London, UK), 1.5 mM MgCl2 (Bioline), 200 mM
dNTPs (Bioline), 200 nM of sense and antisense primers (Sigma,
St. Louis, MO) and 2 U of Biotaq DNA Polymerase (Bioline). PCR
conditions were: 2 minutes at 94uC; 30 seconds at 94uC, 30
seconds at 55uC, 30 seconds at 72uC, for 20–30 cycles (Table S5);
and 10 minutes at 72uC. PCR products were separated by
horizontal electrophoresis for 30 minutes at a constant voltage
(100 V) in a 1% agarose gel, using SYBR Safe (Invitrogen) to
visualize bands.
Real-time PCR
Quantitative gene expression was studied by real time PCR.
Primer sequences are shown in Table S6. The reaction mixture
was: 0.2 mL of cDNA, 12.5 mL of SYBR Green PCR Master Mix
(Applied Biosystems, Forster City, CA) and 300 nM of sense and
antisense primers (Sigma). All amplifications were done in a 7300
Real Time PCR System (Applied Biosystems) using the following
conditions: 2 minutes at 50uC; 10 minutes at 95uC; 15 seconds at
95uC and 1 minute at 60uC, for 40 cycles. RNA expression of each
gene was normalized with HPRT expression. A tumor/normal
expression ratio was calculated. In the case of the cell lines, this
ratio was obtained dividing the normalized RNA expression of the
gene in the cell line by its normalized expression in NHBE cells. In
patient samples, the ratio was calculated dividing the normalized
gene expression in the tumor tissue by the normalized gene
expression in its corresponding normal tissue.
Microsatellite Analysis
Microsatellites at 21q22.3 were analyzed to determine loss of
heterozygosity (LOH). Informative microsatellites (those with
maximum heterozygosity) were selected using different databases
(www.ensembl.org, www.ncbi.nlm.nih.gov, and www.cephb.fr).
Characteristics of the selected microsatellites are shown in Table
S7. PCRs with specific fluorescence primers were done using the
following reaction mixture: 20 ng of DNA, 1 mL of 106 buffer
(Bioline), 2 mM MgCl2, 250 mM dNTPs (Bioline), 250 nM 6-
FAM-labeled sense and antisense primers (Sigma), 0.5 mL of
DMSO (Sigma) and 0.4 U of Biotaq DNA polymerase (Bioline).
PCRs were carried out in a DNA Engine Tetrad 2 Peltier Thermal
Cycler (Bio-Rad, Hercules, CA), using this program: 10 minutes at
95uC; 30 seconds at 95uC, 30 seconds at annealing temperature
(Table S7), and 45 seconds at 72uC, for 40 cycles; and 10 minutes
at 72uC. One microliter from a 1:10 dilution of the amplification
product was added to 20 mL of formamide and 0.2 mL of
GeneScan-500 LIZ Size Standard (Applied Biosystems). The
mixture was separated by capillary electrophoresis in a 3130xl
Genetic Analyzer and data were analyzed by Gene Mapper
Software 3.7 (both from Applied Biosystems). LOH was
determined by this ratio: (N1/N2)/(T1/T2), where N1 and N2
represent the areas of the two alleles peaks in the normal sample
and T1 and T2 are the areas of the allele peaks in the
corresponding tumor sample. LOH was considered present when
the ratio was ,0.5 or .2.
SNP Analysis
A single nucleotide polymorphism (SNP) located within the
ADAR2 gene (rs1051367) was analyzed by PCR. Primers used to
amplify the region containing this SNP were: sense, 59-
CTTCCTCTGGGTTGCTTTC-39; antisense, 59-
TCAGGGCGTGAGTGAG-39. One hundred nanograms of
genomic DNA were used to run a 30-cycle PCR. Reaction
conditions were the same as those described above for conven-
tional PCR. The amplification product was sequenced by capillary
electrophoresis using BigDye Terminator 3.1 in a 3130xl Genetic
Analyzer (Applied Biosystems). Sequences were analyzed using
Chromas Lite 2.01 (Technelysium, Brisbane, Australia).
Statistical Analysis
Significant differences in expression levels of RNA metabolism-
related genes were analyzed by ANOVA. LOH frequencies were
compared using the Mann-Whitney U-test. Kaplan-Meier plots
were used to illustrate differences in progression according to the
mRNA levels of the selected genes. mRNA expression data were
obtained from an extensive study of lung adenocarcinomas [26].
Patients with adjuvant chemo- or radiotherapy were excluded.
Information about overall survival and gene expression was
available from 213 patients. Clinicopathological features of these
patients are shown in Table S8. Expression was dichotomized
using the median value. Overall survival (censored at 60 months)
was used as the outcome variable. Probesets used were:
203865_s_at (ADAR2), 200058_s_at (ASCC3L1), 201475_s_at
(MARS), 208787_s_at (MRPL3), 215157_s_at (PABPC1),
211318_s_at (RAE1), 208821_s_at (SNRPB), 203316_s_at
(SNRPE). For the combined analysis of prognostic genes, patients
were divided into three groups: patients with no deregulating
events, patients with one to three events, and patients with four or
five events. A deregulating event was defined by a high expression
of an up-regulated gene (MARS, RAE1, SNRPB or SNRPE) or a
low expression of the donwregulated one (ADAR2). Significant
differences in survival were analyzed using the log-rank test.
Suvival was correlated with age, gender, smoking status, stage,
differentiation grade and the prognostic score in a univariate Cox
proportional hazards analysis. Multivariate analysis was performed
on parameters found to be significant on univariate analysis. p-
values ,0.05 were considered statistically significant.
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